7,9-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,3-b]indole | 1009631-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7,9-dimethyl-1,2,3,4,5,6-hexahydroazepino[4,3-b]indole
• CAS: 1009631-27-9
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: QWLRSLYPEVNTQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF
  申请人：Borisovich Frolov Yevgeniy

  公开号：US20120040965A1

  公开（公告）日：2012-02-16

  The invention relates to novel chemical compounds, searching for novel physiologically active substances, leader compounds, “molecular tools”, and drug candidates obtained on the basis of screening of combinatorial and focused libraries of the said compounds, and also to pharmaceutical composition, methods for preparation and use thereof. The invention proposes hydrogenated azepino[4,3-b]indoles of general formula 1 or racemates, optical isomers, geometrical isomers, mixtures of optical or geometrical isomers, pharmaceutically acceptable salts and/or hydrates thereof: wherein: solid line together with the dotted line ( ) represents a single or double bond; R 1 and R 2 independently of each other are amino group substituents selected from hydrogen; optionally substituted C 1 -C 8 alkyl with substituents selected from optionally substituted aryl or 5-6-membered azaheterocyclyl; C 1 -C 8 alkoxycarbonyl; optionally substituted phenyl; optionally substituted carbonylamino or thiocarbonylamino; substituted acyl; C 1 -C 8 alkylsulfonyl; optionally substituted arylsulfonyl; upon that, the substituents in the said R 1 and R 2 independently selected from C 1 -C 8 alkyl, halogen atoms, nitro group, carboxy group, alkoxy, aryl; R i n represents one or more “substituents of cyclic structure” of the same or different structure selected from hydrogen, halogen, C 1 -C 8 alkyl, C 6 -C 10 aryl, 5-6-membered azaheterocyclyl.

  本发明涉及新型化合物，寻找新的生理活性物质，领先化合物，“分子工具”和药物候选物，这些化合物是基于筛选所述化合物的组合和专注库获得的，并且还涉及制备和使用其药物组合物的方法。 本发明提出了通式1的氢化氮杂七环[4,3-b]吲哚或外消旋体、光学异构体、几何异构体、光学或几何异构体的混合物、药学上可接受的盐和/或水合物： 其中：实线和虚线（）表示单键或双键；R1和R2独立地是氨基基团取代物，选自氢原子；可选取代的C1-C8烷基，所述取代基被选自可选取代的芳基或5-6成员的杂氮杂环基；C1-C8烷氧羰基；可选取代的苯基；可选取代的羰基氨基或硫代羰基氨基；取代的酰基；C1-C8烷基磺酰基；可选取代的芳基磺酰基；在此基础上，所述R1和R2中的取代基独立地选自C1-C8烷基、卤原子、硝基、羧基、烷氧基、芳基；Rin代表相同或不同结构的一个或多个“环结构取代基”，选自氢原子、卤素、C1-C8烷基、C6-C10芳基、5-6成员的杂氮杂环基。
• FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130210803A1

  公开（公告）日：2013-08-15

  This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及熔合四环吡啶[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130217675A1

  公开（公告）日：2013-08-22

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2184064A2

  公开（公告）日：2010-05-12

  The invention relates to novel ligands of 5-HT6 receptor, to a pharmaceutical composition containing said novel ligands of 5-HT6 receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT6 receptors are playing an essential role. Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT6 ligands. Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C1-C5-alkyl optionally substituted by: C6-C10-arylaminocarbonyl, heterocyclyl, C6-C10-arylaminocarbonyl, C6-C10-arylaminothiocarbonyl, C5-C10-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R1k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C1-C5-alkyl, C1-C5-alkoxy, C1-C5-alkenyl, C1-C5-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line (---) represents a single or a double bond; n=1,2 or 3.

  本发明涉及 5-HT6 受体的新型配体、含有所述 5-HT6 受体新型配体作为活性成分的药物组合物以及用于人类和温血动物治疗中枢神经系统疾病和病症的新型药物，在中枢神经系统疾病和病症的发病机制中，5-HT6 受体诱导的神经介导系统发挥着重要作用。 通式 1 的杂杂环化合物或外消旋体，或光学或几何异构体，或其药学上可接受的盐和/或水合物可用作 5-HT6 配体。 其中，R2 和 R3 相互独立地代表一个氨基取代基，该取代基选自氢；取代的羰基；取代的氨基羰基；取代的氨基硫代羰基；取代的磺酰基；任选被以下取代的 C1-C5- 烷基：C6-C10-芳基氨基羰基：C6-C10-芳基氨基羰基、杂环烷基、C6-C10-芳基氨基羰基、C6-C10-芳基氨基硫代羰基、C5-C10-氮杂环芳基、任选取代的羧基、硝基、任选取代的芳基；R1k 代表 1 至 3 个相互独立的环状体系取代基，选自氢、任选取代的 C1-C5- 烷基、C1-C5-烷氧基、C1-C5-烯基、C1-C5-炔基、卤素、三氟甲基、CN 基、羧基、任选取代的芳基、任选取代的杂环基、取代的磺酰基、任选取代的羧基；伴随虚线 (---) 的实线代表单键或双键；n=1、2 或 3。
• US9034865B2
  申请人：——

  公开号：US9034865B2

  公开（公告）日：2015-05-19